日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer

一项评估氟维司群联合阿贝西利治疗激素受体阳性晚期或复发性子宫内膜癌的II期研究

Green, Angela K; Zhou, Qin; Iasonos, Alexia; Zammarrelli, William A 3rd; Weigelt, Britta; Ellenson, Lora H; Chhetri-Long, Rashmi; Shah, Pooja; Loh, Jade; Hom, Vania; Selenica, Pier; Erinjeri, Joseph; Petkovska, Iva; Chandarlapaty, Sarat; Cohen, Seth; Grisham, Rachel; Konner, Jason; Rubinstein, Maria M; Tew, William; Troso-Sandoval, Tiffany; Aghajanian, Carol; Makker, Vicky

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses

纳武利尤单抗治疗错配修复缺陷或高突变妇科癌症:一项包含生物标志物分析的 2 期试验

Friedman, Claire F; Manning-Geist, Beryl L; Zhou, Qin; Soumerai, Tara; Holland, Aliya; Da Cruz Paula, Arnaud; Green, Hunter; Ozsoy, Melih Arda; Iasonos, Alexia; Hollmann, Travis; Leitao, Mario M Jr; Mueller, Jennifer J; Makker, Vicky; Tew, William P; O'Cearbhaill, Roisin E; Liu, Ying L; Rubinstein, Maria M; Troso-Sandoval, Tiffany; Lichtman, Stuart M; Schram, Alison; Kyi, Chrisann; Grisham, Rachel N; Causa Andrieu, Pamela; Wherry, E John; Aghajanian, Carol; Weigelt, Britta; Hensley, Martee L; Zamarin, Dmitriy

A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)

一项针对 HER2 过表达的晚期子宫内膜癌和癌肉瘤的 2 期 zanidatamab 试验 (ZW25-IST-2)

Lumish, Melissa; Chui, M Herman; Zhou, Qin; Iasonos, Alexia; Sarasohn, Debra; Cohen, Seth; Friedman, Claire; Grisham, Rachel; Konner, Jason; Kyi, Chrisann; Rubinstein, Maria; Troso-Sandoval, Tiffany; Aghajanian, Carol; Makker, Vicky

HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer

HER2 基因肿瘤内异质性与复发性高级别子宫内膜癌对曲妥珠单抗和曲妥珠单抗-美坦新治疗的耐药性相关

Shen, Sherry; Ma, Weining; Brown, David; Da Cruz Paula, Arnaud; Zhou, Qin; Iaosonos, Alexia; Tessier-Cloutier, Basile; Ross, Dara S; Troso-Sandoval, Tiffany; Reis-Filho, Jorge S; Abu-Rustum, Nadeem; Zhang, Yanming; Ellenson, Lora H; Weigelt, Britta; Makker, Vicky; Chui, M Herman

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study

度伐利尤单抗联合或不联合曲美利尤单抗治疗持续性或复发性子宫内膜癌或子宫内膜癌肉瘤患者:一项随机开放标签的2期研究

Rubinstein, Maria M; Doria, Eric Rios; Konner, Jason; Lichtman, Stuart; Zhou, Qin; Iasonos, Alexia; Sarasohn, Debra; Troso-Sandoval, Tiffany; Friedman, Claire; O'Cearbhaill, Roisin; Cadoo, Karen; Kyi, Chrisann; Cohen, Seth; Soldan, Krysten; Billinson, Eric; Caird, Imogen; Jang, Dasom; Eid, Khalil; Shah, Pooja; Guillen, Joyce; Aghajanian, Carol; Zamarin, Dmitriy; Makker, Vicky

Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial

卵巢癌二次细胞减灭术后(伴或不伴腹腔热灌注化疗)的并发症:一项随机 II 期试验的分析

Praiss, Aaron M; Zhou, Qin; Iasonos, Alexia; Moukarzel, Lea; Dessources, Kimberly; Soldan, Krysten; Su, Katy; Sonoda, Yukio; Roche, Kara Long; Gardner, Ginger J; Troso-Sandoval, Tiffany; Tew, William P; Grisham, Rachel N; Chi, Dennis S; O'Cearbhaill, Roisin E; Zivanovic, Oliver

Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study

恩扎卢胺辅助治疗早期雄激素受体阳性三阴性乳腺癌:一项可行性研究

Walsh, Elaine M; Gucalp, Ayca; Patil, Sujata; Edelweiss, Marcia; Ross, Dara S; Razavi, Pedram; Modi, Shanu; Iyengar, Neil M; Sanford, Rachel; Troso-Sandoval, Tiffany; Gorsky, Mila; Bromberg, Jacqueline; Drullinsky, Pamela; Lake, Diana; Wong, Serena; DeFusco, Patricia Ann; Lamparella, Nicholas; Gupta, Ranja; Tabassum, Tasmila; Boyle, Leigh Ann; Arumov, Artavazd; Traina, Tiffany A

Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study

二次细胞减灭术联合卡铂腹腔热灌注化疗治疗铂敏感复发性卵巢癌:MSK团队卵巢II期研究

Zivanovic, Oliver; Chi, Dennis S; Zhou, Qin; Iasonos, Alexia; Konner, Jason A; Makker, Vicky; Grisham, Rachel N; Brown, Amy K; Nerenstone, Stacy; Diaz, John P; Schroeder, Eric D; Langstraat, Carrie L; Paroder, Viktoriya; Lakhman, Yulia; Soldan, Krysten; Su, Katy; Gardner, Ginger J; Andikyan, Vaagn; Guo, Jianxia; Jewell, Elizabeth L; Long Roche, Kara; Troso-Sandoval, Tiffany; Lichtman, Stuart M; Moukarzel, Lea A; Dessources, Kimberly; Abu-Rustum, Nadeem R; Aghajanian, Carol; Tew, William P; Beumer, Jan; Sonoda, Yukio; O'Cearbhaill, Roisin E

Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial

吉西他滨联合曲妥珠单抗和帕妥珠单抗治疗既往接受过帕妥珠单抗治疗的人表皮生长因子受体2阳性转移性乳腺癌患者的疗效和安全性:一项II期临床试验

Iyengar, Neil M; Smyth, Lillian M; Lake, Diana; Gucalp, Ayca; Singh, Jasmeet C; Traina, Tiffany A; DeFusco, Patricia; Fornier, Monica N; Goldfarb, Shari; Jhaveri, Komal; Modi, Shanu; Troso-Sandoval, Tiffany; Patil, Sujata; Ulaner, Gary A; Jochelson, Maxine; Norton, Larry; Hudis, Clifford A; Dang, Chau T

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study

每周一次紫杉醇联合曲妥珠单抗和帕妥珠单抗治疗HER2过表达转移性乳腺癌患者:一项II期研究的总生存期和更新的无进展生存期结果

Smyth, L M; Iyengar, N M; Chen, M F; Popper, S M; Patil, S; Wasserheit-Lieblich, C; Argolo, D F; Singh, J C; Chandarlapaty, S; Sugarman, S M; Comen, E A; Drullinsky, P R; Traina, T A; Troso-Sandoval, T; Baselga, J; Norton, L; Hudis, C A; Dang, C T